BCRX GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Biocryst Pharmaceuticals Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies.
Did you know?
BCRX's revenue grew at a 61.8% CAGR over the last 6 years.
Current Price
$9.19
+0.33%Profile
Valuation (TTM)
Market Cap$1.93B
P/E7.33
EV—
P/B—
Shares Out210.54M
P/Sales2.21
Revenue$874.84M
EV/EBITDA6.15
Biocryst Pharmaceuticals Inc (BCRX) Quality Analysis
BCRX Profitability
Profitability trend analysis coming soon
BCRX Growth
Growth trend analysis coming soon
BCRX Financial Health
Financial health indicators coming soon
BCRX Quality & Fundamental Analysis
Biocryst Pharmaceuticals Inc (BCRX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Biocryst Pharmaceuticals Inc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Biocryst Pharmaceuticals Inc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of 30.16%. Return on assets (ROA) stands at 51.32%.
with a current ratio of 2.06. Operating margin is 38.98%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Biocryst Pharmaceuticals Inc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.